Background-Periprocedural bridging with unfractionated heparin or low-molecular-weight heparin aims to reduce the risk of thromboembolic events in patients receiving long-term vitamin K antagonists. Optimal periprocedural anticoagulation has not been established. Methods and Results-MEDLINE, EMBASE, and Cochrane databases (2001-2010) were searched for English-language studies including patients receiving heparin bridging during interruption of vitamin K antagonists for elective procedures. Data were independently collected by 2 investigators (ϭ0.90). The final review included 34 studies with 1 randomized trial. Thromboembolic events occurred in 73 of 7118 bridged patients (pooled incidence, 0.9%; 95% confidence interval [CI], 0.0.0 -3.4) and 32 of 5160 nonbridged patients (pooled incidence, 0.6%; 95% CI, 0.0 -1.2). There was no difference in the risk of thromboembolic events in 8 studies comparing bridged and nonbridged groups (odds ratio, 0.80; 95% CI, 0.42-1.54). Bridging was associated with an increased risk of overall bleeding in 13 studies (odds ratio, 5.40; 95% CI, 3.00 -9.74) and major bleeding in 5 studies (odds ratio, 3.60; 95% CI, 1.52-8.50) comparing bridged and nonbridged patients. There was no difference in thromboembolic events (odds ratio, 0.30; 95% CI, 0.04 -2.09) but an increased risk of overall bleeding (odds ratio, 2.28; 95% CI, 1.27-4.08) with full versus prophylactic/intermediate-dose low-molecular-weight heparin bridging. Low-thromboembolic-risk and/or non-vitamin K antagonist patient groups were used for comparison. Study quality was poor with heterogeneity for some analyses. Conclusions-Vitamin K antagonist-treated patients receiving periprocedural heparin bridging appear to be at increased risk of overall and major bleeding and at similar risk of thromboembolic events compared to nonbridged patients. Randomized trials are needed to define the role of periprocedural heparin bridging. (Circulation. 2012;126:1630-1639.)
American College of Chest Physicians (ACCP) recommend an individualized approach to determining the need for bridging anticoagulation based on the patient's estimated thromboembolic risk and periprocedural bleeding risk. 1 However, the grades of these recommendations are weak (Level 2C), reflecting the lack of high-quality evidence.
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The risks and benefits of periprocedural bridging anticoagulation were assessed in a systematic review of studies published from 1966 to 2001. 3 However, firm conclusions could not be drawn about the safety and efficacy of bridging and other management strategies mainly because of poorly described bridging regimens and a lack of reliable estimates of associated thromboembolic and bleeding risks. 3 Since this systematic review, multiple large, multicenter studies have assessed standardized periprocedural management strategies, with well-defined bridging regimens and outcomes, and objectively verified adverse events. 4 Given the uncertainty associated with optimal periprocedural anticoagulant management and the use of bridging therapy, we performed a systematic review of studies and a meta-analysis to evaluate the safety and efficacy of periprocedural bridging anticoagulation.
Methods

Data Sources and Searches
We used the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and searched Medline, EMBASE, and Cochrane Collaboration databases for English-language studies published from January 1, 2001, until July 31, 2010, supplemented by manual review of reference lists from the ACCP antithrombotic practice guidelines (eighth and ninth editions; R. Kunz, personal communication, June 30, 2010) . 5 The search strategy was adapted from the ACCP Antithrombotic Practice Guidelines Working Group (ninth edition) and is shown in the Data Supplement ( Figure I 
Study Selection
Studies were selected independently by 2 authors (D.S. and J.Y.), and discrepancies were resolved by consensus of a third author (A.C.S.). Included studies met all of the following criteria: adult patients (Ն18 years of age), elective invasive procedure or surgery, long-term use of VKA preprocedurally, periprocedural bridging with LMWH in at least some patients studied, and reporting of thromboembolic and bleeding events. Studies with unclear reporting of thromboembolic or bleeding events and studies conducted explicitly in patients with severe renal failure (creatinine clearance Ͻ30 mL/min in whom LMWH bridging would be contraindicated) were excluded. Agreement between reviewers for study selection was assessed with the statistic. 6
Data Extraction and Quality Assessment
Two reviewers independently collected data on study design, patient characteristics, bridging strategies (timing of interruption and resumption of oral anticoagulation, timing of heparin bridging, type and dose of heparin), and types of procedures performed. Patients were classified as bridged if they received any heparin bridging in the perioperative period. Treatment-dose LMWH was defined as follows: dalteparin 200 IU ⅐ kg Ϫ1 ⅐ d Ϫ1 or 100 to 120 IU/kg twice daily, enoxaparin 1.5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 or 1 mg/kg twice daily, ardeparin 100 to 130 IU/kg twice daily, and tinzaparin 175 IU ⅐ kg Ϫ1 ⅐ d Ϫ1 . All other doses were considered intermediate-or prophylactic-dose bridging regimens. High and low thromboembolic risk classification was based on definitions used in the primary studies.
Patients were classified as nonbridged if they underwent periprocedural interruption of oral anticoagulation without heparin bridging. Patients not receiving long-term oral anticoagulation but undergoing the procedure(s) under study were also classified as nonbridged. Patients who did not discontinue oral anticoagulation in the periprocedural period were classified as continued oral anticoagulation.
The primary outcomes were thromboembolic events and major bleeding events. Secondary outcomes were overall bleeding, arterial thromboembolic events (stroke, transient ischemic attack, systemic embolism, and myocardial infarction), venous thromboembolic events (deep vein thrombosis, pulmonary embolism), and death. We used the reported definitions of major bleeding provided in the primary studies. These included need for transfusion, bleeding at a critical site, decrease in hemoglobin Ͼ2 g/L, requirement for surgical hemostasis, need for rehospitalization, and fatal bleeding. I indicates intervention; LMWH, low-molecular-weight heparin; NR, not reported; C, comparator; VKA, vitamin K antagonist; and UFH, unfractionated heparin. No bridging refers to VKA oral anticoagulant discontinuation without heparin bridging. Non-VKA refers to patients not receiving long-term oral anticoagulation but undergoing surgical or invasive procedure under study.
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Study quality was assessed with criteria adapted from the ninth edition of the ACCP Antithrombotic Working Group for quality assessment of single-cohort observational studies (R. Kunz, personal communication). Disagreements on study data extraction were resolved by consensus or discussion with a third reviewer.
Data Synthesis and Analysis
Descriptive statistics were reported as means and 95% confidence intervals (CIs) for continuous variables and as proportions for categorical variables. For studies with bridged and nonbridged groups, data were pooled by use of the Mantel-Haenszel method, and a random-effects model was performed with generation of odds ratios (ORs) through the use of RevMan version 5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2011). 7 Pooled incidence rates of thromboembolic and bleeding events in all studies (including single-arm studies) were calculated with the statistical method of Laird and Mosteller 8 as previously reported. 9 The I 2 test was used to assess heterogeneity. 10 Descriptive statistics were generated with SPSS version 13.0 (SPSS Inc, Apache Software Foundation).
Results
Study Identification, Selection, and Characteristics
As shown in Figure 1 , our search strategy yielded 1171 potentially eligible studies; we excluded 1122 studies after screening titles and abstracts using predefined inclusion and exclusion criteria. The remaining 49 studies were subjected to a more detailed review, and an additional 15 were excluded for the following reasons: unclear or absent outcome reporting (nϭ7), non-English language (nϭ3), renal failure (nϭ2), no long-term anticoagulation with VKA (nϭ1), no LMWH (nϭ1), and nonelective procedure (nϭ1). In total, 34 studies were included in this systematic review. The study selection process demonstrated good interobserver agreement (ϭ0.90).
Study characteristics are provided in Table 1 . Median duration of patient follow-up was 30 days (range, 7-90 days). A prespecified bridging protocol was in place before enrollment in 22 studies (65%). The majority of studies (59%) did not report the source of study funding. In the remaining studies, funding was obtained from industry (21%), nonindustry (15%), or both (3%). Indications for anticoagulation of bridged patients were reported in 30 studies as atrial fibrillation (44%), mechanical heart valve (24%), previous venous thromboembolism (22%), and other (10%; 
Study Quality
As shown in Table 3 , study quality was generally poor with potential for biased comparisons of outcomes. Only 1 study used a randomized design; the remaining 33 used an observational design. Thirteen studies reported nonbridged comparative data based on patients at low thromboembolic risk and/or those not treated long-term with oral anticoagu- 
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lation. Five studies included a group who continued oral anticoagulation.
Thromboembolic Events
Thromboembolic outcome data were available for all 34 studies that included a total of 7118 patients receiving any periprocedural heparin bridging. Overall, thromboembolic events occurred in 73 of 7118 bridged patients (pooled incidence rate, 0.9%; 95% CI, 0.0 -3.4) and 32 of 5160 nonbridged patients (pooled incidence rate, 0.6%; 95% CI, 0.0 -1.2; Table 4 ). Arterial thromboembolic events represented approximately half of thromboembolic events in both bridged (nϭ50 of 73, 68%) and nonbridged (nϭ15 of 32, 47%) patients. Arterial thromboembolic and/or venous thromboembolic events were not reported in all studies, as reflected by the patients at risk in each treatment group shown in Table 4 . In 6 studies that stratified patients by thrombo-embolic risk, patients not at high thromboembolic risk receiving prophylactic dose or no bridging had an overall thromboembolic event rate of 0.6% (11 of 1702). In 8 studies that assessed thromboembolic events in both bridged and nonbridged patients, the outcome occurred in 19 of 1691 bridged and 32 of 3493 nonbridged patients ( Figure 2 ). There was no reduction in the risk of thromboembolic events with the use of heparin bridging (OR, 0.80; 95% CI, 0.42-1.54; Figure 2 ). There was also no difference in the risk of arterial thromboembolic (OR, 0.83; 95% CI, 0.36 -1.95) or venous thromboembolic (OR, 1.00; 95% CI, 0.32-3.12) events between bridged and nonbridged patients. The risk of thromboembolic events was similar in patients receiving full-dose versus intermediate-or prophylactic-dose LMWH (2 studies; OR, 0.30; 95% CI, 0.04 -2.09). We found no heterogeneity for thromboembolic, arterial thromboembolic, and venous thromboembolic outcomes across studies (I 2 ϭ0%). In a sensitivity analysis, removal of nonanticoagulated patients resulted in a similar risk of thromboembolic events (OR, 0.82; 95% CI, 0.42-1.64).
Bleeding Events
Overall bleeding was included as an outcome in all 34 studies, whereas major bleeding was reported in 24 studies. The criteria for major bleeding were provided in 21 studies: need for transfusion (nϭ19), bleeding at a critical site (nϭ17), Ͼ2-g/L decrease in hemoglobin (nϭ16), surgical hemostasis required (nϭ11), fatal bleeding (nϭ9), and need for hospitalization (nϭ7). Pooled incidence rates of overall and major bleeding in the total bridged cohort were 13.1% (34 studies; 95% CI, 0.0 -45.2) and 4.2% (24 studies; 95% CI, 0.0 -11.3), respectively (Table 4 ). In the nonbridged cohort, pooled incidence rates of overall and major bleeding were 3.4% (13 studies; 95% CI, 1.1-5.8) and 0.9% (5 studies; 95% CI, 0.2-1.6), respectively. Three studies assessed bleeding complications stratified by procedural bleed risk, with bleeding complication (including major bleeding) rates of 7.8%, 1.85%, and 20%, respectively, in mostly bridged patients undergoing major surgery or high-bleed-risk procedures compared with bleed rates of 6.0%, 0.74%, and 0.5% in patients undergoing non-high-bleed-risk/invasive procedures or minor surgery.
There was an increased risk of overall bleeding (13 studies; OR, 5.40; 95% CI, 3.00 -9.74) and major bleeding (5 studies; OR, 3.60; 95% CI, 1.52-8.50) in bridged versus nonbridged patients (Figures 3 and 4 ). There was also an increased risk of overall bleeding in patients receiving full versus prophylactic-or intermediate-dose LMWH (OR, 2.28; 95% CI, 1.27-4.08). We found significant heterogeneity for overall bleeding (I 2 ϭ77%) and major bleeding (I 2 ϭ52%) outcomes across studies.
In a sensitivity analysis, removal of nonanticoagulated patients resulted in a similar risk of overall bleeding (OR, 3.79; 95% CI, 1.98 -7.23). The risk of major bleeding was unchanged.
Discussion
We reviewed 34 studies that assessed perioperative thromboembolic and bleeding events in Ͼ12 000 patients undergoing elective surgical invasive or invasive procedures. Of these, 7118 patients on long-term VKA received periprocedural heparin bridging with LMWH during VKA interruption. The principal finding from this study is that patients who receive heparin bridging appear to have an increased risk of overall and major bleeding events in the periprocedural period but a similar risk of thromboembolic events compared with patients who receive no periprocedural bridging. Thus, heparin bridging conferred a Ͼ5-fold (OR, 5.40) increased risk for overall bleeding and a Ͼ3-fold (OR, 3.60) increased risk for major bleeding, whereas the risk of thromboembolic events was not significantly different in bridged and nonbridged patients (OR, 0.80). Use of therapeutic-dose LMWH bridging was also associated with an increased risk of bleeding 
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Periprocedural Bridging Anticoagulation compared with prophylactic-or intermediate-dose LMWH (OR, 2.28), although thromboembolic event rates did not significantly differ.
The main strength of our study is that it represents, to the best of our knowledge, the largest systematic review and meta-analysis of the efficacy and safety of periprocedural bridging anticoagulation. Our study contributes data from 34 additional studies and Ͼ7000 patients since the systematic review by Dunn and colleagues 3 in 2003. We provide a characterization of contemporary bridging practice, demonstrating that bridging is accomplished predominantly with LMWH that is discontinued Ն12 hours before and restarted within 24 hours after procedures. Our observed overall pooled thromboembolic event rate of 0.9% in bridged patients is similar to the 1.6% reported in the above-mentioned review. 3 However, in that study, bleeding event data were difficult to interpret, thereby precluding specific conclusions on periprocedural bleeding complications. All studies in our review included bleeding outcome data and provided more reliable estimates of overall (13.1%) and major (4.2%) bleeding rates associated with bridging anticoagulation.
Several study limitations may affect the validity of our findings. First, we acknowledge that only a proportion of included studies contributed to the random effects model, and caution is required in the interpretation of our results. The internal validity of our data is supported by a lack of heterogeneity in analyses of thromboembolic events, both arterial and venous, when assessed in patients who received bridging or no bridging and in full-dose versus prophylactic-or intermediate-dose LMWH patient cohorts. However, there was significant heterogeneity for analyses of bleeding events in bridged versus nonbridged patients, which was likely related to variability in procedural bleeding risk and nonstandard definitions of bleeding events across studies. This is particularly relevant to the major bleeding data that were derived from 24 studies with a wide range of definitions and surgical procedures. Only a few studies systematically reported bleeding risk according to the type of procedure. Second, the large majority of studies were observational; most were cohort studies lacking control groups. When control groups were included, they consisted of lowthromboembolic-risk and/or non-VKA patient groups for comparative analysis, especially in assessments of baseline procedure-related bleeding rates. Therefore, the treatment and comparison groups may have had different thromboembolic risks at baseline, and because we were unable to perform regression analyses to account for potential differences in baseline risks, there is a risk of systemic bias in regard to which patients were bridged and not bridged. It is possible that with a majority of bridged patients considered high risk for thromboembolic events (57% in 19 studies), such high-thromboembolicrisk patients may have preferentially received bridging therapy whereas low-thromboembolic-risk patients did not. Thus, bridging may have reduced a very high thromboembolic rate in the high-risk, bridged group to that of the lower-thromboembolicrisk, nonbridged patients.
Our findings are relevant to VKA-treated patients who require temporary discontinuation of oral anticoagulation for elective surgical or invasive procedures and address first how to administer bridging anticoagulation-its timing and dose regimen used-and second which patients should receive bridging. In regard to the first point, our findings suggest for the first time that bridging therapy, especially with therapeutic-dose regimens, may be associated with increased postprocedural bleeding complications and should be used cautiously, especially after the procedure. Although the present analysis did not allow us to precisely differentiate bleed risk according to the procedure type, this finding should be more applicable to high-bleed-risk procedures such as major surgery, which had the highest bleeding rates with bridging therapy. Approaches that have been proposed to mitigate this risk but have not been studied in prospective clinical studies include delaying the administration of postprocedural therapeutic-dose bridging at least 24 hours after the procedure (assuming hemostasis is secured) and for 48 to 72 hours in high-bleed-risk cases. 1 Alternatively, prophylactic-or intermediate-dose LMWH bridging regimens, which may be associated with a decreased risk of bleeding events, can be considered. In regard to the second point, our findings raise important questions about the overall premise of heparin bridging, regardless of the dose regimen, to minimize the risk for periprocedural thromboembolic events during temporary interruption of oral anticoagulant therapy. Our findings indicate that bridging therapy should be avoided in patients not at high thromboembolic risk, given the low thromboembolic rates in the absence of bridging therapy. However, a major potential confounder in these studies is that bridged patients may have been at higher risk for thromboembolic events than nonbridged patients. Overall, what is unclear is whether the higher rate of periprocedural bleeding associated with heparin bridging is an acceptable tradeoff for a presumed (but unproven) decreased risk for thromboembolism, especially in the high-thromboembolic-risk patients. An attempt to quantify the relative clinical impact of death and disability in atrial fibrillation patients suggests that compared with ischemic strokes, major extracranial bleeding, hemorrhagic stroke, and subdural hemorrhage have relative weights of 0.75, 1.60, and 0.43 respectively. 45 Our study also should be considered within the context of emerging novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban, which have the potential to displace warfarin and, because of their more rapid offset and onset of action compared with warfarin, may obviate the need for perioperative bridging. However, bridging therapy may also be applicable to patients on these novel agents. For example, selected patients receiving dabigatran (with a half-life of 12-17 hours) may require 3 to 5 days of periprocedural interruption, and recent data from the large Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial in atrial fibrillation revealed that Ϸ16% of patients in the dabigatran groups underwent heparin bridging therapy. 46, 47 Finally, our study emphasizes the need for standard definitions of procedural bleeding risk and bleeding outcomes, including major bleeding. To this end, the International Society on Thrombosis and Hemostasis Control of Anticoagulation Subcommittee has recently endorsed recommendations to standardize reporting of patient/procedural thrombo-embolic and bleed risk and outcomes, including major bleeding, and thereby to enable outcome pooling and acrossstudy comparisons. 48 
Conclusions
We found that VKA-treated patients who require an elective surgical or invasive procedure and receive periprocedural bridging anticoagulation with LMWH appear to be at increased risk of overall and major bleeding and at similar risk of thromboembolic events compared with nonbridged patients. The ACCP and other antithrombotic guidelines advocate that bridging anticoagulation should be undertaken with consideration of individual patient thromboembolic risk and procedural bleeding risk by balancing expected benefits and harms. 1 The present analysis suggests that bridging anticoagulation, especially in therapeutic-dose regimens and in patients not at high thromboembolic risk undergoing highbleed-risk procedures, should be avoided in the periprocedural setting. The methodological limitations of our analyses, however, preclude definitive conclusions about the relative efficacy and safety of bridging. Given the large number of patients who require periprocedural anticoagulation management, coupled with the paucity of high-quality studies, randomized trials are urgently needed to determine the role, if any, of bridging anticoagulation and to better inform practices concerning the dose and timing of periprocedural anticoagulation if bridging is used. To address these aims, 2 large randomized, placebo-controlled trials (Effectiveness of Bridging Anticoagulation for Surgery [BRIDGE] and A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin [PERIOP-2]) assessing bridging with therapeutic-dose LMWH are ongoing. 49, 50 
